Company intelligence / Profile preview
Beijing Geek Gene Technology
- Ownership
- Private
- Development stage
- Other
Overview
Beijing Geek Gene Technology is developing autologous tumor-reactive T cell therapies for advanced malignant solid tumors. The company leverages single-cell multi‑omics sequencing and innovative cell reprogramming platforms to support its drug development. At least one program is in the clinical stage, with a focus on neoplasms.[1][4]
- Therapeutic areas
- OncologyDermatologyGastroenterology
- Modalities
- T lymphocyte cell therapyCell therapy (general)Single-cell multi-omics sequencing (enabling technology)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Beijing Geek Gene Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Geek Gene Technology.